<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-id journal-id-type="publisher-id">wox</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization Journal</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3512732</article-id><article-id pub-id-type="doi">10.1097/01.WOX.0000411601.97066.34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts of the XXII World Allergy Congress</subject></subj-group><subj-group subj-group-type="heading"><subject>Poster Session</subject></subj-group><series-title>Immunotherapy</series-title></article-categories><title-group><article-title>486&#x02003;Therapeutic Effect and Security in Asthmatics Adult Patients Treated with Dermatophagoides Pteronyssinus Allergen Sublingual Immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>Jos&#x000e9;</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Ra&#x000fa;l</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Labrada</surname><given-names>Alexis</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Alvarez</surname><given-names>Mirta</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ronquillo</surname><given-names>Mercedes</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>Mayda</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Navarro</surname><given-names>B&#x000e1;rbara</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mateo</surname><given-names>Maytee</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Oliva</surname><given-names>Yunia</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>Iris</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Enriquez</surname><given-names>Irene</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Allergology Department, University Hospital Calixto Garc&#x000ed;a, Havana City, Cuba</aff><aff id="aff2"><label>2</label>Allergens, National Center of Bioproducts, Havana City, Cuba</aff><aff id="aff3"><label>3</label>Allergens, National Center of Bioproducts, Mayabeque, Cuba</aff><aff id="aff4"><label>4</label>Pedro Fonseca Docent Policlinic, Havana City, Cuba.</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><volume>5</volume><issue>Suppl 2</issue><issue-title>Abstracts of the XXII World Allergy Congress, 4&#x02013;8 December, 2012 Canc&#x000fa;n, M&#x000e9;xico</issue-title><fpage seq="c">S171</fpage><lpage>S171</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by World Allergy Organization</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="waoj-5-S171b.pdf"/><abstract><sec><title>Background</title><p>The specific active immunotherapy, employing vaccine of allergen of mite is a treatment considered as effective for the respiratory allergy and asthma. The sublingual route has minor risk of systematises reactions. The objective of this study was to determine the therapeutic effect and security of sublingual immunotherapy (ITSL) employing the standard vaccine VALERGEN-DP (BIOCEN, CUBA) in a population of asthmatic Cuban patients.</p></sec><sec><title>Methods</title><p>A phase II Clinical Trials double blind, placebo controlled in a total of 40 adult patients with mild or moderate asthma and specific sensibility preponderant to this mite. Half of patients received drops by sublingual route with growing doses up to 2000 UB.</p></sec><sec><title>Results</title><p>The treatment was effective in the reduction of clinical symptoms and medication intake as compared to conventional treatment in control group. The cutaneous sensibility to this mite was significant reduced, increasing in 1.9 log; the amount of necessary allergen to provoke a positive Prick Test. An improvement of the lung function was observed with a significant reduction (<italic>P</italic> &#x0003c; 0.05) of expiratory pick flow variability. The frequency of local reactions were only 0.58% of administration.</p></sec><sec><title>Conclusions</title><p>The VALERGEN-DP vaccine is an effective treatment and profitable against asthma in our population and guarantee its generalization in the Allergy Services of our health system.</p></sec></abstract></article-meta></front></article>